This Monday the update by ADSE of some prices of drugs and intraoperative prostheses comes into force, as provided for in the general rules of the table of the agreed regime.
This new update follows the revision of the agreed regime chart, which came into force in March and which led to increases in co-payments in various consultations, such as psychiatry, pediatrics and obstetrics.
ADSE acknowledges that “price increases are not pleasant”, but clarifies that the “lack of access” to services was not a solution
“The Table of the Agreed Regime, which is expected to enter into force on May 1, only contemplates the setting of maximum prices for some medications and some intraoperative prostheses, in addition to the best evaluation of fourteen state-of-the-art surgical techniques, namely, laparoscopy, robotics, lasers, ultrasonic scissors, neuronavigation, among others,” an official ADSE source told Lusa.
According to the same source, this new update also includes “an innovative means of diagnosis for lung cancer, which includes bronchoscopy and bronchial echoendoscopy for morphological evaluation of mediastinal nodes and the respective biopsy.”
In a note published in placeThe Institute for the protection and assistance in the case of officials reports that “updates on oncological drugs and intraoperative prostheses continue at no cost to the beneficiaries, being fully financed by the ADSE.”
On March 9, ADSE considered that the revision of the price list of the agreed regime was “inevitable and urgent”, after the General and Supervision Board (CGS) of ADSE and unions criticized the impact of the measure on the beneficiaries .
ADSE will increase the amounts it pays to individuals for the second time in just over a year
“The revision operated was inevitable and urgent, given the growing and successive increases in health goods and services. But not only. If, on the one hand, the beneficiaries reported to ADSE difficulties and impediments in accessing medical care, on the other hand, the providers complained about the amounts paid by ADSE for certain and certain medical acts, for being below the prices charged in the current context. of inflation and did not cover their real costs”, ADSE explained at the time.
According to the institute, this situation caused some medical acts to be withdrawn from the agreements and invoiced to the beneficiaries for free, which “caused enormous instability and discontent among the beneficiaries.”
“It is in this context that ADSE had to intervene, reviewing the price list in a general way by 5% and in higher percentages the areas of radiology (RX, CT, magnetic resonance imaging, ultrasound, etc.), surgery (area of urology, gynecology and otorhinolaryngologists) and certain specialty consultations (pediatrics, oncology, gynecology, obstetrics, psychiatry, rheumatology and dermato-venereology)”, continues the institute.
In the document, the ADSE indicates that the institute “continues to claim 80% of the increase, leaving the beneficiaries with 20%.”
According to an opinion of the CGS, the new ADSE tables translate into an increase of 7.75 million euros in the expenses of the beneficiaries and must be “supported in full” by ADSE.
Source: Observadora
